summari opportun meet manag
earlier today key takeaway confid
top-lin growth acceler tax bill view gener
posit new restructur program expect drive margin
improv ep leverag diabet growth anticip
improv pain therapi franchis
expect improv upcom quarter riptid aspir
system launch evaluationnew cathet like month
away fim first-in-man still expect robot platform
ye sale expect appear
lower preliminari fy commentari point anoth
year mid-singl digit top-lin growthwhil bottom-lin
outlook less clear time
confid acceler earlier week
investor confer reiter guidanc
guidanc impli acceler growth
organ remain confid step-up
growth driven improv diabet growth sensor suppli
improv new product introduct cvg cardiac
vascular group resolut onyx evolut
improv rtg restor therapi group perform
full-benefit revamp mitg minim
new tax view gener posit manag said
impact tax reform gener posit
expect modest benefit tax rate importantli
expect nearli access ou cash
today also expect larg one-tim repatri bill
paid next year bill expect
depend happen puerto rico tax litig
impact annual cash flow
plan off-set impact disciplin reinvest un-
trap cash consist current capit alloc prioriti
expect free cash flow grow roughli in-lin earn
on-going basi regard potenti ep impact tax rate
current model assum bp
reduct compani tax rate model would result
increment ep
continu next page
pleas see page rate definit import disclosur
requir analyst certif estimates/forecast
well fargo secur llc seek busi compani
cover research report result investor awar
firm may conflict interest could affect object report
investor consid report singl factor make
compani data secur llc estim reuter
ep exclud amort reflect combin follow
acquisit cov
compani prioriti stock list
compani data secur llc estim reuter
new restructur program introduc unveil enterpris excel restructur program
earlier week program center leverag mdt size scale target
annual increment save aggreg expect
achiev save expect incur restructur expens
time period plan reinvest part save compani also expect see benefit
margin ep leverag
diabet growth expect improv fy continu expect diabet
busi improv meaning sensor suppli issu subsid said
capac expans effort remain track compani still expect abl meet full sensor
demand end addit compani expect benefit anima transit
name partner-of-choic expect see convers rate roughli
anima patient least equal current market share compani expect patient
warranti come regular cadenc estim transit
take month word potenti anima benefit expect occur period
time separ hope posit launch guardian connect stand-alone cgm
continu glucos monitor system end manag said publicli target
double-digit diabet growth
pain therapi expect improv come quarter said expect pain therapi
busi show improv high-single-digit declin seen manag expect
spinal cord stimul pain pump segment combin sale show
growth move forward bullish combin compani evolv workflow
new intelli hardwar pump fda lift warn letter novemb separ
said seen smaller expect impact bsx entri us db deep brain stimul
market though remain earli launch recal receiv fda approv
vercis db system parkinson diseas get addit visibl mdt neuromod
busi compani analyst meet nan north american neuromodul societi friday
riptid launch evalu new cathet expect month receiv fda
approv aspir pump treat stroke decemb four month file
second aspir system fda approv stroke us system riptid
combin new pump mdt exist arc cathet compani evalu launch plan
previous compani fda approv catheter/pump combo treat stroke
feedback consult suggest arc ok cathet necessarili competit
pen ace expect bring new cathet market consult
suggest better arc anticip get new cathet approv quick month
possibl month suggest launch expect remain formid
competitor stroke market solitair stent retriev catheter/pump system
aspir would expect competitor like compet aggress technolog
mitg robot still target fim sale expect appear
lower said continu expect mitg minim invas therapi group robot program
enter first-in-man fim end follow commerci launch manag
expect first launch unspecifi em emerg market countri expect commerci
revenu manag said level contribut function
compani receiv regulatori approvalwhich lead us believ back previou
target laid last analyst day meet mitg growth roughli
earli thought fy expect formal give fy guidanc call
manag provid high-level color top-lin next fiscal year meet base
mdt commentari would expect mid-single-digit sale growth guidanc compar ex-fx basi
adj pmr divestitur wed note also provid earli fy top-lin thought divis
earn callit impress guidepost remain unchang time
regard said today expect drive meaning oper margin expans non-
growth quantifi potenti level non- ep growth word
say expect double-digit non-gaap ep growth next year compani non-committ
double-digit ep growth meetingmdt could simpli tri manag street expect
head next year
price target nc
price target assum cy cash ep estim risk includ
weak key end market greater share loss model delay product launch
believ deliv averag organ growth due lull major new product launch
combin competitor headwind
found minneapolis-bas lead global medic technolog compani
focus provid therapi chronic diseas compani four primari busi cardiac
vascular restor therapi minim invas therapi diabet revenu
